A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C, Lacroix L, Benisvy D, Taïeb D, Bardet S, Terroir-Cassou-Mounat M, Anizan N, Bouvier-Morel E, Lamartina L, Lion G, Betrian S, Sajous C, Schiazza A, Garcia ME, Ciappuccini R, Schlumberger M, Al Ghuzlan A, Godbert Y, Borget I.
Leboulleux S, et al. Among authors: sajous c.
Clin Cancer Res. 2023 Jul 5;29(13):2401-2409. doi: 10.1158/1078-0432.CCR-23-0046.
Clin Cancer Res. 2023.
PMID: 37074727
Free article.
Clinical Trial.